Bahia Sandeep S, Holt Peter J, Ray Kausik K, Ussher Michael, Poloniecki Jan D, Sharma Rajan, Bown Matthew J, Hinchliffe Robert J, Thompson Matthew M, Karthikesalingam Alan
Department of Outcomes Research, St George's Vascular Institute, St George's Healthcare NHS Trust, Room 4.007, Blackshaw Road, London, SW17 0QT, UK.
Department of Cardiovascular Sciences, St George's University of London, London, SW17 0RE, UK.
Trials. 2015 Apr 15;16:162. doi: 10.1186/s13063-015-0669-2.
Abdominal and thoracic aortic aneurysms (A/TAA) are an important cause of mortality amongst the older population. Although A/TAA repair can be performed with low peri-operative risk, overall life expectancy remains poor in the years that follow surgery. The majority of deaths are caused by heart attack or stroke, which can both be prevented by cardiac rehabilitation (CR) in patients with clinically-manifest coronary artery disease. A Cochrane review has urged researchers to widen the use of CR to other populations with severe cardiovascular risk, and patients surviving A/TAA repair appear ideal candidates. However, it is unknown whether CR is feasible or acceptable to A/TAA patients, who are a decade older than those currently enrolling in CR. Aneurysm-CaRe is a feasibility randomised controlled trial (RCT) that will address these issues.
Aneurysm-CaRe is a pilot RCT of CR versus standard care after A/TAA repair, with the primary objectives of estimating enrolment to a trial of CR after A/TAA repair and estimating compliance with CR amongst patients with A/TAA. Aneurysm-CaRe will randomise 84 patients at two sites. Patients discharged from hospital after elective A/TAA repair will be randomised to standard care or enrolment in their local CR programme with a protocolised approach to medical cardiovascular risk reduction. The primary outcome measures are enrolment in the RCT and compliance with CR. Secondary outcomes will include phenotypic markers of cardiovascular risk and smoking cessation, alongside disease-specific and generic quality-of-life measures.
ISRCTN 65746249 5 June 2014.
腹主动脉瘤和胸主动脉瘤(A/TAA)是老年人群死亡的重要原因。尽管A/TAA修复手术围手术期风险较低,但术后多年总体预期寿命仍较差。大多数死亡是由心脏病发作或中风引起的,而临床确诊的冠状动脉疾病患者可通过心脏康复(CR)预防这两种情况。Cochrane综述敦促研究人员将CR的使用范围扩大到其他有严重心血管风险的人群,而A/TAA修复术后存活的患者似乎是理想人选。然而,对于比目前参加CR的患者大十岁的A/TAA患者来说,CR是否可行或可接受尚不清楚。Aneurysm-CaRe是一项可行性随机对照试验(RCT),将解决这些问题。
Aneurysm-CaRe是一项A/TAA修复术后CR与标准护理对比的试点RCT,主要目标是估计A/TAA修复术后CR试验的入组率以及估计A/TAA患者对CR的依从性。Aneurysm-CaRe将在两个地点对84名患者进行随机分组。择期A/TAA修复术后出院的患者将被随机分配接受标准护理或参加当地的CR项目,并采用标准化方法降低医疗心血管风险。主要结局指标是RCT的入组率和对CR的依从性。次要结局将包括心血管风险的表型标志物和戒烟情况,以及疾病特异性和一般生活质量指标。
ISRCTN 65746249 2014年6月5日。